Donanemab | search
Click here to view Donanemab news from 60+ newspapers.
Bookmark or Share- FDA Approves Kisunla (Donanemab) | Alzheimer's AssociationAlzheimer’s Association Welcomes U.S. FDA Approval of Kisunla (Donanemab) CHICAGO, July 2, 2024 — The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to approve Kisunla™ (donanemab, Eli Lilly) for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild ...
- Donanemab - WikipediaDonanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. Donanemab was developed by Eli Lilly and Company. The most common side effects include amyloid-related imaging abnormalities and headache. Donanemab was approved for medical use in the United States in July 2024.
- FDA approves treatment for adults with Alzheimer’s diseaseThe U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild...
- Donanemab: Uses, Side Effects, Dosage, Warnings - Drugs.comDonanemab (Kisunla) is used to treat Alzheimer’s disease to help slow down the decline in memory, thinking, and daily functioning. Includes side effects, dose, and warnings.
- Donanemab in Early Alzheimer’s Disease | NEJMDonanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer’s disease. Methods. We conducted a phase 2 trial of donanemab...
More
